Recursion Pharmaceuticals

Recursion Pharmaceuticals (operating at recursion.com) is a clinical-stage TechBio company pioneering AI-driven drug discovery. Founded by visionaries and headquartered in Salt Lake City, Recursion is redefining the pharmaceutical industry by leveraging advanced artificial intelligence to decode biology at an unprecedented scale. Unlike traditional drug discovery methods, which rely on slow, trial-and-error processes, Recursion employs proprietary AI platforms to accelerate the identification of novel drug targets and optimize compound design. Its technology integrates high-throughput screening, computational biology, and machine learning to analyze vast datasets, enabling faster and more precise drug development. This empowers biopharmaceutical companies and researchers to expedite breakthroughs in treating complex diseases, from rare genetic disorders to infectious diseases. Backed by a $50 million investment from NVIDIA and achieving a market valuation milestone with $785 million in unaudited figures, Recursion is at the forefront of industrializing drug discovery to radically improve patient outcomes.